Target intelligence / Profile preview

7,8-diaminopelargonic acid synthase (DAPA synthase)

Target
DAPA synthase
Molecular classification
Enzyme, Transferase (specifically pyridoxal phosphate-dependent aminotransferase), Transaminase
01

Overview

7,8-Diaminopelargonic acid synthase (DAPA synthase; EC 2.6.1.62/2.6.1.105), commonly referred to as 7,8-diaminononanoate synthase in functional nomenclature, is a pyridoxal phosphate-dependent aminotransferase that catalyzes the transfer of an amino group from S-adenosyl-L-methionine (SAM) or L-lysine to 7-keto-8-aminopelargonic acid (KAPA), producing 7,8-diaminononanoate (DAPA) in the third-to-last step of de novo biotin biosynthesis. This process is essential for microbial viability and is absent in animals, making the enzyme a valuable antimicrobial drug target. DAPA synthase is encoded by the bioA (or occasionally bioK) gene in various bacteria and is part of a tightly regulated biotin operon cluster

Other names
7,8-diaminononanoate synthase7,8-diaminopelargonic acid synthaseDAPA synthaseDAPA aminotransferase7,8-diaminononanoate transaminasebioA gene product (EC 2.6.1.62, EC 2.6.1.105)
02

Mechanism of action

Enzyme inhibitors would typically act by blocking the aminotransferase activity, ultimately depleting biotin synthesis in susceptible bacteria or fungi

03

Biological functions

Biotin biosynthesisAmino group transfer (transamination)
04

Disease associations

Infection (target for antibiotic development)
05

Safety considerations

Targeting this enzyme is generally safe for humans, as the human host lacks de novo biotin biosynthesis. However, microbiome effects from broad inhibition of gut flora could be a risk
06

Interacting drugs

There are no approved drugs directly targeting DAPA synthase, but several experimental inhibitors (such as substrate mimics or mechanism-based inhibitors) have been reported in the biotin synthesis pathway for antimicrobial development
07

Biomarkers

Activity or expression of bioA, or accumulation of biotin pathway intermediates (such as KAPA or DAPA), may serve as molecular indicators in functional or mechanistic studies; no validated clinical biomarkers yet

Beyond the preview

Go deeper on 7,8-diaminopelargonic acid synthase (DAPA synthase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7,8-diaminopelargonic acid synthase (DAPA synthase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call